Acadia Healthcare Co. (ACHC) Upgraded to “Hold” by Zacks Investment Research
According to Zacks, “Acadia Healthcare’s second quarter 2016 results failed to impress us. The lack of visibility in the company's UK operations is a major concern, which will limit Acadia’s growth prospects in the near term. However, owing to a large addressable market in the U.S. and the U.K, Acadia has managed to bag strong revenues and earnings in the second quarter. We note that the company is a premier name in the behavioral healthcare market and has planned to divest massively, which is expected to address the integration headwinds in UK. Meanwhile, addition of new beds at Acadia’s facilities, opening of de novo facility, and new acquisitions in US are expected to fortify the company’s market position in the rest of full-year 2016.”
Several other analysts have also recently commented on the stock. Royal Bank Of Canada decreased their price target on shares of Acadia Healthcare from $86.00 to $78.00 and set an outperform rating for the company in a report on Monday, August 1st. Leerink Swann restated a buy rating and set a $80.00 price target on shares of Acadia Healthcare in a report on Sunday, August 28th. Jefferies Group restated a buy rating and set a $85.00 price target on shares of Acadia Healthcare in a report on Monday, June 27th. RBC Capital Markets restated an outperform rating and set a $78.00 price target (down from $86.00) on shares of Acadia Healthcare in a report on Monday, August 1st. Finally, Robert W. Baird decreased their price target on shares of Acadia Healthcare from $67.00 to $66.00 and set an outperform rating for the company in a report on Thursday, September 15th. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Acadia Healthcare presently has a consensus rating of Buy and a consensus price target of $77.21.
Shares of Acadia Healthcare (NASDAQ:ACHC) opened at 49.15 on Monday. The company’s 50-day moving average is $50.84 and its 200-day moving average is $55.15. The firm has a market capitalization of $4.30 billion, a price-to-earnings ratio of 26.26 and a beta of 0.86. Acadia Healthcare has a 12-month low of $46.99 and a 12-month high of $74.77.
Acadia Healthcare (NASDAQ:ACHC) last released its earnings results on Friday, July 29th. The company reported $0.73 earnings per share for the quarter, hitting the consensus estimate of $0.73. The business had revenue of $756.50 million for the quarter, compared to the consensus estimate of $752.57 million. Acadia Healthcare had a net margin of 6.44% and a return on equity of 9.35%. The firm’s quarterly revenue was up 66.8% compared to the same quarter last year. During the same period last year, the firm posted $0.57 earnings per share. On average, equities analysts forecast that Acadia Healthcare will post $2.63 earnings per share for the current fiscal year.
In related news, COO Ronald Morgan Fincher sold 8,800 shares of the business’s stock in a transaction on Monday, August 8th. The shares were sold at an average price of $52.56, for a total transaction of $462,528.00. Following the transaction, the chief operating officer now owns 120,780 shares of the company’s stock, valued at $6,348,196.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Reeve B. Waud sold 1,360,977 shares of the business’s stock in a transaction on Friday, September 16th. The stock was sold at an average price of $48.52, for a total transaction of $66,034,604.04. Following the transaction, the director now directly owns 55,673 shares in the company, valued at approximately $2,701,253.96. The disclosure for this sale can be found here. 17.20% of the stock is currently owned by insiders.
A number of institutional investors have recently made changes to their positions in the company. Commonwealth Equity Services Inc raised its position in shares of Acadia Healthcare by 14.0% in the first quarter. Commonwealth Equity Services Inc now owns 27,037 shares of the company’s stock worth $1,490,000 after buying an additional 3,320 shares during the period. Aperio Group LLC raised its stake in shares of Acadia Healthcare by 39.2% in the first quarter. Aperio Group LLC now owns 6,032 shares of the company’s stock valued at $332,000 after buying an additional 1,699 shares during the period. Teachers Advisors Inc. raised its stake in shares of Acadia Healthcare by 29.5% in the first quarter. Teachers Advisors Inc. now owns 342,061 shares of the company’s stock valued at $18,851,000 after buying an additional 77,973 shares during the period. Prudential Financial Inc. raised its stake in shares of Acadia Healthcare by 98.2% in the first quarter. Prudential Financial Inc. now owns 94,340 shares of the company’s stock valued at $5,199,000 after buying an additional 46,750 shares during the period. Finally, BlackRock Fund Advisors raised its stake in shares of Acadia Healthcare by 16.6% in the first quarter. BlackRock Fund Advisors now owns 776,809 shares of the company’s stock valued at $42,810,000 after buying an additional 110,692 shares during the period.
Acadia Healthcare Company Profile
Acadia Healthcare Company, Inc is a provider of behavioral healthcare services. The Company operates in two segments: U.S. Facilities and U.K. Facilities. The Company develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States, the United Kingdom and Puerto Rico.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acadia Healthcare Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare Co. and related companies with MarketBeat.com's FREE daily email newsletter.